Spinifex Pharmaceuticals, which focuses on the development of new drugs for the treatment of chronic pain, has announced that it has agreed to the sale of Spinifex to Novartis International AG for an upfront cash consideration of US$200m, plus undisclosed clinical development and regulatory milestone payments.
The acquisition is centred on Spinifex’s lead candidate EMA401, a novel angiotensin II type 2 (AT2) receptor antagonist, being developed as a potential first-in-class oral treatment for chronic pain, particularly neuropathic pain, without central nervous system (CNS) side effects. Neuropathic pain is defined by the International Association for the Study of Pain as that “caused…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
